MEVPRO-3: A randomized phase 3 study of mevrometostat plus enzalutamide in androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-sensitive prostate cancer (mCSPC)
Web preview is not available
Try directly downloading the file.